In the latest recitation, Bristol-Myers Squibb is paying $800 million upfront for rights to a HER3-directed ADC from China’s SystImmune in a deal that could swell to $8.4 billion. It gives BMS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback